Pertussis
Pertussis epidemics were relatively common in Europe during the 16th, 17th and 18th centuries. Outbreaks were also common in America. By the 1930s, 73 percent of all U.S. children under 10 were exposed to the disease and a small percentage died. Today, pertussis is rarely fatal. However, when infants under six months contract the disease, it can be serious and life-threatening. There is no specific treatment for pertussis. Antibiotics and cough suppressants have been used, but with little effect, and are generally not recommended.
The first “whole-cell” pertussis vaccine was developed in the early 1900s and put into general use during the mid-1930s and early 1940s. In 1946, the pertussis vaccine was mixed with vaccines for diptheria and tetanus. This became known as DPT, the world’s first “three-in-one” combination shot. In 1981, Japan replaced DPT with DTaP because it contains a supposedly safer “acellular” form of pertussis. The United States switched from DPT to DTaP in 1996.
The current DTaP vaccine developed for infants 6 weeks to 7 years of age contains Bordetella pertussis antigens, Corynebacterium diptheriae toxoid, plus Clostridium tetani cultures “grown in a Peptone-based medium containing a bovine extract.” This combination vaccine also contains 170 mcg of aluminum, “a trace amount of thimerosal” (a mercury derivative), gelatin, polysorbate 80, and polio virus and pepatitis B as well - a “five-in-one” shot! It also contains 850 mcg (!) of aluminum, neomycin sulfate, polymyxin B, polysorbate 80, residual formaldehyde, and yeast protein. (The DPT vaccine that was eventually removed form the market after 50 years of pediatric use contained 25 mcg of thimerosal per dose.)
In 1954, researchers at the U.S. Public Health Service developed the first test to determine whether the pertussis vaccine is safe for children: they injected the vaccine into the bellies of young mice to see if they would die. If the mice lived and gained weight, the vaccine was considered safe and was approved by the FDA. The United States never conducted its own clinical tests in children to determine whether the pertussis vaccine is safe. Instead, it relied on data collected by Great Britain during the 1950s on children between six months and one-and-a-half years of age. Even though 42 of these children had convulsions within 28 days, 80 percent of the babies were 14 months of age or older, and the tests were designed to measure the efficacy —not safety— of the vaccine, U.S. health authorities used these results as evidence that the vaccine is safe to give to babies as young as six weeks of age. In fact, a two month old baby weighing less than ten pounds receives the same dose of pertussis vaccine as a 50 pound child entering preschool.
The pertussis vaccine may cause fever as high as 106 degrees, pain, swelling, diarrhea, projectile vomiting, excessive sleepiness, high-pitched screaming (not unlike the so-called cri encephalique, or encephalitic scream associated with central nervous system damage), inconsolable crying bouts, seizures, convulsions, collapse, shock, breathing problems, brain damage, and sudden infant death syndrome (SIDS). In one report, serious reactions (including grand mal epilepsy and encephalopathy) were shown to be as high as one in 600. In another study, approximately one out of every 200 children who received the full DPT series suffered severe reactions (shock-collapse or convulsions).
The manufacturer lists several serious adverse reactions that have been reported after its DTaP vaccine was licensed and mass marketed. These include anaphylaxis, encephalopathy, grand mal convulsion, thrombocytopenia, hypotonia, neuropathy, autism, apnea and sudden infant death syndrome (SIDS). Several other serious reactions were reported by DTaP manufacturers (including the maker of the five-in-one shot); swelling of the mouth, difficulty breathing, cranial mononeuropathy, brachial neuritis, Guillain-Barre syndrome, demyelinating diseases of the central nervous system, neuroblastoma, gastroenteritis, bronchiolitis, asthma, diabetes, chronic neutropenia, seizures, convulsions, bulging fontanelle, cyanosis, lymph-adenopathy, arthralgia, myalgia, angioedema, alopecia, apnea, and death.
Vaccine Safety Manual by Neil Z Miller